Phaos Technology Holdings (Cayman) (POAS) Cash & Equivalents (2024 - 2025)

Phaos Technology Holdings (Cayman) (POAS) posted Cash & Equivalents of $54989.0 for Q4 2025, down 43.26% on a QoQ basis from $96918.3 in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) Cash & Equivalents (2024 - 2025) Analysis & Trends

Phaos Technology Holdings (Cayman)'s Cash & Equivalents history runs 2 years deep, the most recent figure standing at $54989.0 for Q4 2025.

Quarterly Cash & Equivalents changed N/A year-over-year to $54989.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $54989.0 (changed N/A YoY) and the FY2025 annual result came in at $97007.0, down 94.35% from the prior year.
Cash & Equivalents was $54989.0 for Q4 2025 at Phaos Technology Holdings (Cayman), down from $96918.3 in the prior quarter.
Across five years, Cash & Equivalents topped out at $1.7 million in Q2 2024 and bottomed at $54989.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Abbott Laboratories	182.66 Bn	175.36 Bn	6.27 Bn	6.80 Bn
2	Stryker	128.55 Bn	125.68 Bn	3.81 Bn	2.88 Bn
3	Medtronic	108.38 Bn	99.16 Bn	6.41 Bn	1.95 Bn
4	Boston Scientific	68.11 Bn	66.66 Bn	3.61 Bn	1.45 Bn
5	Edwards Lifesciences	47.19 Bn	43.52 Bn	1.29 Bn	2.45 Bn
6	Dexcom	28.54 Bn	27.42 Bn	750.30 Mn	1.12 Bn
7	GE HealthCare Technologies	28.37 Bn	26.09 Bn	1.98 Bn	2.29 Bn
8	Smith & Nephew	26.90 Bn	26.33 Bn	-	557.00 Mn
9	Koninklijke Philips	25.53 Bn	22.40 Bn	2.07 Bn	3.03 Bn
10	Phaos Technology Holdings (Cayman)	6.17 Mn	6.12 Mn	-	54,989.00

Download Data